Cargando…
Recent Developments in the Treatment of Childhood Atopic Eczema
Even with the most careful application of conventional treatment, atopic eczema can be a disabling handicap in severely affected children. In refractory cases the conventional therapeutic options— potent topical steroids or the use of systemic steroids—are potentially hazardous and associated with r...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Royal College of Physicians of London
1991
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5377204/ https://www.ncbi.nlm.nih.gov/pubmed/2066937 |
_version_ | 1782519267706535936 |
---|---|
author | David, T. J. |
author_facet | David, T. J. |
author_sort | David, T. J. |
collection | PubMed |
description | Even with the most careful application of conventional treatment, atopic eczema can be a disabling handicap in severely affected children. In refractory cases the conventional therapeutic options— potent topical steroids or the use of systemic steroids—are potentially hazardous and associated with relapse after therapy has been discontinued. The main drawbacks to recent experimental approaches, such as oral cyclosporin, photochemotherapy or interferon-γ, are relapse after cessation of therapy and potentially serious side-effects. Avoidance of certain foods, pets and house dust mites is an option, the major drawbacks being the lack of tests to identify triggers or predict response, and the possible nutritional or psychological hazards of elimination diets. Difficulties with these approaches emphasise the need for close attention to the details of conventional treatment. |
format | Online Article Text |
id | pubmed-5377204 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1991 |
publisher | Royal College of Physicians of London |
record_format | MEDLINE/PubMed |
spelling | pubmed-53772042019-01-22 Recent Developments in the Treatment of Childhood Atopic Eczema David, T. J. J R Coll Physicians Lond Overview Even with the most careful application of conventional treatment, atopic eczema can be a disabling handicap in severely affected children. In refractory cases the conventional therapeutic options— potent topical steroids or the use of systemic steroids—are potentially hazardous and associated with relapse after therapy has been discontinued. The main drawbacks to recent experimental approaches, such as oral cyclosporin, photochemotherapy or interferon-γ, are relapse after cessation of therapy and potentially serious side-effects. Avoidance of certain foods, pets and house dust mites is an option, the major drawbacks being the lack of tests to identify triggers or predict response, and the possible nutritional or psychological hazards of elimination diets. Difficulties with these approaches emphasise the need for close attention to the details of conventional treatment. Royal College of Physicians of London 1991-04 /pmc/articles/PMC5377204/ /pubmed/2066937 Text en © Journal of the Royal College of Physicians of London 1991 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits non-commercial use and redistribution provided that the original author and source are credited. |
spellingShingle | Overview David, T. J. Recent Developments in the Treatment of Childhood Atopic Eczema |
title | Recent Developments in the Treatment of Childhood Atopic Eczema |
title_full | Recent Developments in the Treatment of Childhood Atopic Eczema |
title_fullStr | Recent Developments in the Treatment of Childhood Atopic Eczema |
title_full_unstemmed | Recent Developments in the Treatment of Childhood Atopic Eczema |
title_short | Recent Developments in the Treatment of Childhood Atopic Eczema |
title_sort | recent developments in the treatment of childhood atopic eczema |
topic | Overview |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5377204/ https://www.ncbi.nlm.nih.gov/pubmed/2066937 |
work_keys_str_mv | AT davidtj recentdevelopmentsinthetreatmentofchildhoodatopiceczema |